Microcap Ledger Scienture Holdings, Inc. $SCNX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Commack, NY
- Fiscal year end
- December 31
- Shares outstanding
- 41,064,146 [10-Q 2026-08-13]
What the company doesAI summary of filing
Scienture Holdings, Inc. is a clinical-stage specialty pharmaceutical company focused on the commercialization and development of products for cardiovascular and central nervous system diseases. The company has one FDA-approved commercial product, Arbli (losartan potassium oral suspension), launched in the third quarter of 2025, and is commercializing a second product, Rezenopy (naloxone HCl nasal spray 10mg), under an exclusive license agreement. Scienture's development pipeline includes product candidates in various stages of clinical development for migraine, thrombosis, and postoperative pain, with the company generating revenue through product sales while continuing to advance its pipeline through clinical studies. [10-K 2026-03-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $400.0K | −$6.22M | −$6.05M | $8.19M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $431.6K | −$41.51M | −$13.38M | $6.66M | [10-K 2026-03-30] |
| FY ended Dec 2024 | $136.6K | $13.63M | −$14.27M | $308.1K | [10-K 2026-03-30] |
- Quarterly cash burn
- −$3.03M
- Cash runway Estimate
- ~8.1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-03-26 | 12,515,019 | [10-K 2025-03-26] |
| 2025-05-12 | 13,116,429 | [10-Q 2025-05-12] |
| 2025-08-12 | 16,131,180 | [10-Q 2025-08-12] |
| 2025-11-12 | 40,630,815 | [10-Q 2025-11-12] |
| 2026-03-27 | 40,630,815 | [10-K 2026-03-30] |
| 2026-04-30 | 40,630,815 | [10-K/A 2026-04-30] |
| 2026-05-15 | 40,630,815 | [10-Q 2026-05-15] |
| 2026-08-13 | 41,064,146 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2025-08-25; declared effective 2025-08-27 [S-3 2025-08-25]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-10-17. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-10-17 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-10-17] |
| 2025-05-22 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-22] |
| 2025-01-08 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-01-08] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-02-20 | Shankar Hariharan | grant | 500,000 | — | [4 2026-03-12] |
| 2026-02-20 | Narasimhan Mani | grant | 500,000 | — | [4 2026-03-12] |
| 2025-10-01 | Shankar Hariharan | grant | 300,000 | — | [4 2026-03-12] |
| 2025-10-01 | Narasimhan Mani | grant | 300,000 | — | [4 2026-03-12] |
| 2025-04-14 | Shankar Hariharan | grant | 750,000 | — | [4 2026-03-12] |
| 2025-04-14 | Narasimhan Mani | grant | 750,000 | — | [4 2026-03-12] |
| 2025-03-10 | Shankar Hariharan | other | 30,000 | — | [4 2026-03-12] |
| 2025-03-10 | Narasimhan Mani | other | 20,000 | — | [4 2026-03-12] |
| 2024-09-19 | Shankar Hariharan | other | 1,916,816 | — | [4 2026-03-12] |
| 2024-09-19 | Shankar Hariharan | other | 356,480 | — | [4 2026-03-12] |
| 2024-09-19 | Narasimhan Mani | other | 1,357,538 | — | [4 2026-03-12] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-07 | 8-K | Change to security holder rights; Charter, bylaws or fiscal year change; Regulation FD disclosure |
| 2026-09-18 | DEF 14A | Proxy statement |
| 2026-09-14 | 8-K | Regulation FD disclosure |
| 2026-09-08 | PRE 14A | Proxy statement |
| 2026-08-20 | 8-K | Results of operations |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-05-29 | 8-K | Director or officer change |
| 2026-05-22 | 8-K | Results of operations |
| 2026-05-15 | 10-Q | Quarterly report |
| 2026-05-05 | 8-K | Regulation FD disclosure |
| 2026-05-01 | 8-K | Material agreement entered; New financial obligation |
| 2026-04-30 | 10-K/A | Amended report |
Alerts for $SCNX
Email me when Scienture Holdings, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.